Biblio Discovery — Demo Discovery Service

6 hasil untuk "Per Pfeiffer"

Menampilkan 1–6 · 0,53 detik · RSS

  1. Artikel Jurnal Teks lengkap

    High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer

    Christina Siesing; Halfdan Sorbye; Anca Dragomir dkk.

    PLOS ONE, Vol. 12 No. 8 · 2017 · Inggris · PLOS Scopus

    Background: High expression of the RNA-binding motif protein 3 (RBM3) has been shown to correlate, with prolonged survival in several malignant diseases and with the benefit of platinum-based chemotherapy in ovarian cancer. The aim of this study was to evaluate RBM3 in metastatic colorectal cancer…

  2. Artikel Jurnal Teks lengkap

    High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort

    Halfdan Sorbye; Anca Dragomir; Magnus Sundström dkk.

    PLOS ONE, Vol. 10 No. 6 · 2015 · Inggris · PLOS Scopus

    RAS and BRAF mutations impact treatment and prognosis of metastatic colorectal cancer patients (mCRC), but the knowledge is based on trial patients usually not representative for the general cancer population. Patient characteristics, treatment and efficacy according to KRAS, BRAF and MSI status…

  3. Artikel Jurnal Teks lengkap

    miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3 rd Line Cetuximab and Irinotecan

    Jakob V. Schou; Simona Rossi; Benny V. Jensen dkk.

    PLoS ONE, Vol. 9 No. 6 · 2014 · Inggris · PLOS Scopus

    …variable in the full cohort, resulted in a hazard ratio (HR) of 2.38 per IQR (CI 95%: 1.8–3.1, P-value = 2.86e−07, Bonferroni adjusted, univariable analysis) and a HR = 1.75 per IQR (CI 95%: 1.24–2.48, P-Wald = 1.45e-03) in the multivariable analysis adjusted for gender, age, KRAS, PI3KCA and…

  4. Artikel Jurnal Teks lengkap

    Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study

    Line S. Tarpgaard; Tormod K. Guren; Bengt Glimelius dkk.

    PLoS ONE, Vol. 9 No. 2 · 2014 · Inggris · PLOS Scopus

    Background: We aim to test the hypothesis that high plasma YKL-40 is associated with short progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer (mCRC) treated with first-line oxaliplatin and 5-flourouracil with or without cetuximab. Patients and…

  5. Artikel Jurnal Teks lengkap

    Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer

    Nicolai A. Schultz; Ib J. Christensen; Jens Werner dkk.

    PLoS ONE, Vol. 8 No. 6 · 2013 · Inggris · PLOS Scopus

    Purpose: We tested the hypothesis that high plasma YKL-40 and IL-6 associate with pancreatic cancer and short overall survival. Patients and Methods: In all, 559 patients with pancreatic cancer from prospective biomarker studies from Denmark (n = 448) and Germany (n = 111) were studied. Plasma…

  6. Artikel Jurnal Teks lengkap

    Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab

    Mogens K. Boisen; Christian Dehlendorff; Dorte Linnemann dkk.

    PLoS ONE, Vol. 9 No. 10 · 2014 · Inggris · PLOS Scopus

    Purpose: We tested the hypothesis that expression of microRNAs (miRNAs) in cancer tissue can predict effectiveness of bevacizumab added to capecitabine and oxaliplatin (CAPEOX) in patients with metastatic colorectal cancer (mCRC). Experimental Design: Patients with mCRC treated with first line…